Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(3):317–324. doi: 10.1054/bjoc.2001.1925

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial

The ATAC Trialists' Group 1,1
PMCID: PMC2364083  PMID: 11487258

Abstract

The ATAC trial evaluates in a randomized, double-blind design, Arimidex™ (anastrozole) alone or in combination with tamoxifen, relative to tamoxifen alone as 5-year adjuvant treatment in postmenopausal women with early breast cancer. Patients included in the pharmacokinetic (PK) sub-protocol had been in ATAC for ≥3 months, taking their medication in the morning and were 100% compliant for the preceding 14 days. Blood samples were collected 24 ± 4 h after last dose. Trough (Cmin) plasma concentrations of anastrozole, tamoxifen and desmethyltamoxifen (DMT) were measured by validated methods. The PK results were based on a total of 347 patients (131 anastrozole (1 mg o.d.), 111 tamoxifen (20 mg o.d.), 105 anastrozole and tamoxifen (1 and 20 mg o.d. respectively)). The geometric mean steady-state trough plasma concentrations of tamoxifen and DMT were statistically equivalent in patients receiving tamoxifen alone or in combination with anastrozole: geometric mean tamoxifen = 94.8 ng ml−1and 95.3 ng ml−1in tamoxifen alone and combination groups, respectively; geometric mean DMT = 265.1 and 277.6 ng ml−1in the tamoxifen and anastrozole and tamoxifen groups, respectively. The geometric mean anastrozole levels were 27% lower (90% Cl 20–33%;P< 0.001) in the presence of tamoxifen than with anastrozole alone. Baseline plasma oestradiol levels were not obtained in the PK sub-protocol, however, such information was available from a similar ATAC sub-protocol, which evaluated bone mineral density. Mean oestradiol levels were 21.3, 19.3, and 21.6 pmol l−1prior to treatment and 3.7, 20.9 and 3.6 pmol l−1after 3 months in the anastrozole, tamoxifen, and combination groups, respectively (n = 167). On-treatment values were below the detection limit (3 pmol l−1) in 43.6 and 38.5% of the anastrozole alone and anastrozole in combination with tamoxifen groups, respectively. As a result of (a) the lack of effect of anastrozole on tamoxifen and DMT levels and (b) the observed fall in blood anastrozole levels having no significant effect on oestradiol suppression by anastrozole, we conclude that the observed reduction in anastrozole levels by tamoxifen is unlikely to be of clinical significance when anastrozole and tamoxifen are administered together. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: arimidex, tamoxifen, aromatase inhibitor, oestrogen, oestradiol, breast cancer

Full Text

The Full Text of this article is available as a PDF (77.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bock M. J., Bara I., LeDonne N., Martz A., Dyroff M. Validated assay for the quantification of anastrozole in human plasma by capillary gas chromatography-63Ni electron capture detection. J Chromatogr B Biomed Sci Appl. 1997 Oct 24;700(1-2):131–138. doi: 10.1016/s0378-4347(97)00129-1. [DOI] [PubMed] [Google Scholar]
  2. Bonneterre J., Thürlimann B., Robertson J. F., Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M., von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000 Nov 15;18(22):3748–3757. doi: 10.1200/JCO.2000.18.22.3748. [DOI] [PubMed] [Google Scholar]
  3. Brodie A. M., Njar V. C. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol. 1998 Jul;66(1-2):1–10. doi: 10.1016/s0960-0760(98)00022-3. [DOI] [PubMed] [Google Scholar]
  4. Brodie A., Lu Q., Liu Y., Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer. 1999 Jun;6(2):205–210. doi: 10.1677/erc.0.0060205. [DOI] [PubMed] [Google Scholar]
  5. Buzdar A. U., Jonat W., Howell A., Jones S. E., Blomqvist C. P., Vogel C. L., Eiermann W., Wolter J. M., Steinberg M., Webster A. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998 Sep 15;83(6):1142–1152. [PubMed] [Google Scholar]
  6. Buzdar A., Jonat W., Howell A., Jones S. E., Blomqvist C., Vogel C. L., Eiermann W., Wolter J. M., Azab M., Webster A. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996 Jul;14(7):2000–2011. doi: 10.1200/JCO.1996.14.7.2000. [DOI] [PubMed] [Google Scholar]
  7. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  8. Dowsett M., Pfister C., Johnston S. R., Miles D. W., Houston S. J., Verbeek J. A., Gundacker H., Sioufi A., Smith I. E. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res. 1999 Sep;5(9):2338–2343. [PubMed] [Google Scholar]
  9. Dowsett M., Tobias J. S., Howell A., Blackman G. M., Welch H., King N., Ponzone R., von Euler M., Baum M. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer. 1999 Jan;79(2):311–315. doi: 10.1038/sj.bjc.6690050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dukes M. The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology. 1997;54 (Suppl 2):6–10. doi: 10.1159/000227748. [DOI] [PubMed] [Google Scholar]
  11. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P. O., Lønning P. E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996 Oct;74(8):1286–1291. doi: 10.1038/bjc.1996.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Grodin J. M., Siiteri P. K., MacDonald P. C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207–214. doi: 10.1210/jcem-36-2-207. [DOI] [PubMed] [Google Scholar]
  13. Howell A., Dowsett M. Recent advances in endocrine therapy of breast cancer. BMJ. 1997 Oct 4;315(7112):863–866. doi: 10.1136/bmj.315.7112.863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jaiyesimi I. A., Buzdar A. U., Decker D. A., Hortobagyi G. N. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995 Feb;13(2):513–529. doi: 10.1200/JCO.1995.13.2.513. [DOI] [PubMed] [Google Scholar]
  15. Johnston S. R., Haynes B. P., Sacks N. P., McKinna J. A., Griggs L. J., Jarman M., Baum M., Smith I. E., Dowsett M. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer. Breast Cancer Res Treat. 1993 Dec;28(3):241–250. doi: 10.1007/BF00666585. [DOI] [PubMed] [Google Scholar]
  16. Jordan V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 1976 Jun;12(6):419–424. doi: 10.1016/0014-2964(76)90030-x. [DOI] [PubMed] [Google Scholar]
  17. Knazek R. A., Lippmann M. E., Chopra H. C. Formation of solid human mammary carcinoma in vitro. J Natl Cancer Inst. 1977 Feb;58(2):419–422. doi: 10.1093/jnci/58.2.419. [DOI] [PubMed] [Google Scholar]
  18. Lien E. A., Anker G., Lønning P. E., Solheim E., Ueland P. M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990 Sep 15;50(18):5851–5857. [PubMed] [Google Scholar]
  19. MacDonald P. C., Edman C. D., Hemsell D. L., Porter J. C., Siiteri P. K. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol. 1978 Feb 15;130(4):448–455. doi: 10.1016/0002-9378(78)90287-9. [DOI] [PubMed] [Google Scholar]
  20. Miller W. R., O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids. 1987 Oct-Dec;50(4-6):537–548. doi: 10.1016/0039-128x(87)90037-7. [DOI] [PubMed] [Google Scholar]
  21. Nabholtz J. M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A., von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000 Nov 15;18(22):3758–3767. doi: 10.1200/JCO.2000.18.22.3758. [DOI] [PubMed] [Google Scholar]
  23. Yates R. A., Dowsett M., Fisher G. V., Selen A., Wyld P. J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer. 1996 Feb;73(4):543–548. doi: 10.1038/bjc.1996.94. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES